阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习

doi:10.6040/j.issn.1671-7554.0.2024.0506

摘要/Abstract

摘要： 目的探讨EGFR突变肺腺癌和大疱性类天疱疮之间的关系及阿美替尼的疗效。方法收集1例肺腺癌伴大疱性类天疱疮患者的临床资料,经组织病理学及二代测序基因检测明确病理及分子诊断,并检索相关文献对疾病的发病机制和治疗进行总结分析。结果结合影像及组织病理学明确诊断为转移性肺腺癌伴大疱性类天疱疮,二代测序基因检测结果为EGFR 19外显子缺失敏感突变。给予阿美替尼治疗,定期复查胸部CT,抗肿瘤治疗疗效评价为部分缓解,并且皮肤病变持续好转,患者无明显不良反应。结论 EGFR突变转移性肺腺癌合并大疱性类天疱疮患者可选择靶向药物治疗,阿美替尼有较好疗效及安全性。

关键词: 肺腺癌, 大疱性类天疱疮, 阿美替尼, 靶向治疗

Abstract: Objective To explore the relationship between lung adenocarcinoma with EGFR sensitizing mutation and bullous pemphigoid, as well as the benefit of almonertinib. Methods Clinical data from a case of lung adenocarcinoma complicated with bullous pemphigoid was collected. Pathological and molecular diagnosis was confirmed through histopathological examination and next-generation sequencing genetic testing. Literature review was then conducted to summarize and analyze the diseases pathogenesis and treatment options. Results The diagnosis of metastatic lung adenocarcinoma with bullous pemphigoid was established through imaging and histopathology examination. Next-generation sequencing revealed a sensitizing mutation of exon 19 deletion in the EGFR gene. The patient was treated with almonertinib with regular chest CT evaluations. The anti-tumor treatment efficacy was assessed to be partial response, and the skin lesions continued to improve with no significant adverse reactions. Conclusion Targeted therapies can be considered in patients with EGFR-mutant metastatic lung adenocarcinoma complicated by bullous pemphigoid and almonertinib demonstrates good efficacy and safety.

Key words: Lung adenocarcinoma, Bullous pemphigoid, Almonertinib, Targeted therapy

中图分类号:

R734.2

杨闯,张荣雨,宋彬,王程君,赵文,玄甜甜,李际盛. 阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(12): 32-37.

YANG Chuang, ZHANG Rongyu, SONG Bin, WANG Chengjun, ZHAO Wen, XUAN Tiantian, LI Jisheng. A rare case of lung adenocarcinoma complicated with bullous pemphigoid successfully treated with EGFR-TKI almonertinib[J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 32-37.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Gould Rothberg BE, Quest TE, Yeung SJ, et al. Oncologic emergencies and urgencies: a comprehensive review[J]. CA Cancer J Clin, 2022, 72(6): 570-593.
[3] Balestri R, Magnano M, la Placa M, et al. Malignancies in bullous pemphigoid: a controversial association[J]. J Dermatol, 2016, 43(2): 125-133.
[4] Baum S, Steinberg S, Tzanani I, et al. Prevalence, spectrum and clinical implications of malignancies in patients with bullous pemphigoid[J]. Acta Derm Venereol, 2023, 103: adv00888. doi:10.2340/actadv.v103.3979.
[5] Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update[J]. Am J Clin Dermatol, 2024, 25(2): 195-212.
[6] Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan[J]. J Dermatol Sci, 1995, 9(2): 136-141.
[7] Albadri Z, Thorslund K, Häbel H, et al. Increased risk of squamous cell carcinoma of the skin and lymphoma among 5, 739 patients with bullous pemphigoid: a Swedish nationwide cohort study[J]. Acta Derm Venereol, 2020, 100(17): adv00289. doi:10.2340/00015555-3622.
[8] Ahmed AR, Kalesinskas M, Kooper-Johnson S. Paraneoplastic autoimmune Laminin-332 syndrome(PALS): anti-Laminin-332 mucous membrane pemphigoid as a prototype[J]. Autoimmun Rev, 2023, 22(10): 103444. doi:10.1016/j.autrev.2023.103444.
[9] Kridin K, Hammers CM, Ludwig RJ, et al. Risk of solid malignancies in bullous pemphigoid: a large-scale population-based cohort study[J]. J Dermatol, 2021, 48(3): 317-323.
[10] Varpuluoma O, Jokelainen J, Huilaja L, et al. Solid and hematological malignancies in patients with bullous pemphigoid: a national cohort study[J]. J Am Acad Dermatol, 2024, 90(2): 399-401.
[11] Atzmony L, Mimouni I, Reiter O, et al. Association of bullous pemphigoid with malignancy: a systematic review and meta-analysis[J]. J Am Acad Dermatol, 2017, 77(4): 691-699.
[12] Ong E, Goldacre R, Hoang U, et al. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999-2011[J]. Arch Dermatol Res, 2014, 306(1): 75-80.
[13] Chen CT, Hu HY, Chang YT, et al. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study[J]. Br J Dermatol, 2019, 180(3): 553-558.
[14] Shen WC, Chiang HY, Chen PS, et al. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid[J]. JAMA Dermatol, 2022, 158(2): 167-175.
[15] Lakhdar N, El Khattabi W, Lahroussi M, et al. Cancer pulmonaire à petites cellules associé à une pemphigoïde bulleuse paranéoplasique[J]. Rev De Pneumol Clin, 2014, 70(3): 169-172.
[16] Safini F, Tawfiq N. Pemphigoïde bulleuse paranéoplasique associée à un cancer bronchique[J]. Pan Afr Med J, 2015, 21: 248. doi: 10.11604/pamj.2015.21.248.6034.
[17] Janah H, Mahhou M, Souhi H, et al. Bullous pemphigoid revealing bronchial carcinoma[J]. Pan Afr Med J, 2014, 19: 45. doi:10.11604/pamj.2014.19.45.5160.
[18] Vroman DT, Breckenridge RR, Solomon KD, et al. Bronchogenic squamous cell carcinoma presenting as cicatrizing conjunctivitis[J]. Cornea, 2006, 25(5): 611-613.
[19] Das A, Das S, Das SK, et al. A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung[J]. J Postgrad Med, 2015, 61(3): 197-199.
[20] Shrestha P, George MK, Baidya S, et al. Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy: a case report[J]. J Med Case Rep, 2022, 16(1): 184. doi:10.1186/s13256-022-03323-9.
[21] Kramer N, Müller G, Zierold S, et al. Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid[J]. J Eur Acad Dermatol Venereol, 2024, 38(8): e722-e728.
[22] Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016, 4(5): 383-389.
[23] Stingeni L, Bianchi L, Minotti V, et al. Erlotinib-induced bullous pemphigoid[J]. J Am Acad Dermatol, 2012, 67(5): e199-e201.
[24] Tang K, Seo J, Tiu BC, et al. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy[J]. JAMA Dermatol, 2022, 158(2): 189-193.
[25] 张荣雨,赵文,李洪欣,等.奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报(医学版), 2024, 62(5): 116-120.
[26] Lu S, Dong XR, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27): 3162-3171.
[27] Lu S, Wang QM, Zhang GJ, et al. Efficacy of aumolertinib(HS-10296)in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial[J]. J Thorac Oncol, 2022, 17(3): 411-422.
[28] 邓姝婷,姚煦.肿瘤靶向药物相关皮肤不良反应及发生机制[J].中华临床免疫和变态反应杂志, 2024, 18(2): 181-189. DENG Shuting, YAO Xu. Cutaneous adverse reactions associated with targeted cancer therapy and its pathogenesis[J]. Chinese Journal of Allergy & Clinical Immunology, 2024, 18(2): 181-189.

相关文章 15

[1]	王靖婷,王璟,鲁艺,李静坦,李强,郏雁飞,马晓丽. α5-nAChR与MHC-I在肺腺癌中的表达及相关性[J]. 山东大学学报 (医学版), 2024, 62(5): 72-78.
[2]	孟健丽,王庆港. 生物信息学方法探讨VPS72在肺腺/鳞癌中的表达及潜在作用机制[J]. 山东大学学报 (医学版), 2023, 61(8): 40-49.
[3]	杜圣红,李晓梅,陈晨,王玲. 鼻型弥漫大B细胞淋巴瘤合并肺腺癌1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(8): 111-115.
[4]	刘士标,张淑君,李培龙,杜鲁涛,王传新. cg20657709位点甲基化对肺腺癌早期诊断的初步探讨[J]. 山东大学学报 (医学版), 2023, 61(4): 18-25.
[5]	赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.
[6]	洪慧,张卫海,李惠娴,李伟伟,张金岭. 异时性阑尾印戒细胞癌合并肺腺癌双原发癌1例[J]. 山东大学学报 (医学版), 2022, 60(8): 130-132.
[7]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[8]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[9]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[10]	柴小雪,叶辉,吕欣然,丁续超,甄秋来,杜娟,曹莉莉. POU4F3表达对118例肺腺癌患者预后评估及对肺腺癌细胞株迁移的影响[J]. 山东大学学报 (医学版), 2021, 59(11): 8-18.
[11]	庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28.
[12]	焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.
[13]	陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[14]	杨秀婷,刘启功,左萍,刘正湘,左后娟. CD151-MUT突变对肺腺癌细胞A549迁移的影响及机制[J]. 山东大学学报 (医学版), 2020, 58(3): 81-86.
[15]	王建祥,顾闰夏. 急性髓系白血病的靶向治疗进展[J]. 山东大学学报 (医学版), 2019, 57(7): 6-12.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed